The seeming invincibility of cancerous tumors may be crumbling, thanks to a promising new gene therapy that eliminates the ability of certain cells to repair themselves. Researchers at the Cornell University College of Veterinary Medicine have discovered that inactivation of a DNA repair gene called Hus1 efficiently kills cells lacking p53 -- a gene mutated in the majority of human cancers.
Ithaca, NY (Vocus) November 12, 2009 -- The seeming invincibility of cancerous tumors may be crumbling, thanks to a promising new gene therapy that eliminates the ability of certain cells to repair themselves. Researchers at the Cornell University College of Veterinary Medicine have discovered that inactivation of a DNA repair gene called Hus1 efficiently kills cells lacking p53 -- a gene mutated in the majority of human cancers.
Using a mouse model, senior author Robert Weiss, associate professor of molecular genetics, first author and graduate student Stephanie Yazinski and colleagues explored how cells respond when both genes are inhibited. When they inactivated the Hus1 gene in healthy mammary gland tissues, the researchers report, it caused genome damage and cell death. And when they studied the effects of Hus1 inactivation in p53-deficient cells, which are highly resistant to cell death, they discovered that the ability of Hus1 inactivation to kill cells was even greater.
The study is published in the Nov. 9 issue of the Proceedings of the National Academy of Sciences.
"Our work contributes to an important new understanding of cancer cells and their weaknesses," Weiss said. "The mutations that allow cancer cells to divide uncontrollably also make the cancer cells more dependent on certain cellular processes. We were able to exploit one such dependency of p53-deficient cells and could efficiently kill these cells by inhibiting Hus1."
Weiss and his team have new experiments under way.
"We have proven the power of inhibiting both pathways in normal tissue," said Weiss. "Now we want to extend our knowledge to cancerous tissue and determine if the loss of Hus1 will impact the ability of cancers with p53 mutations to take hold and grow."
Weiss's research was funded by the National Institutes of Health and is now funded through 2013 in part by the American Recovery and Reinvestment Act (ARRA). To date, Cornell has received 124 ARRA grants, totaling more than $99.9 million. Weiss's ARRA funding will support one faculty and two student positions as well as the research activities of several additional lab members.
Written by Stephanie Specchio, communications director for the College of Veterinary Medicine. This article originally appeared in the Cornell Chronicle. Chronicle story link: http://www.news.cornell.edu/stories/Nov09/ARRAWeissPNAS.html
Media Contact:
Joe Schwartz
(607) 254-6235
Joe (dot) Schwartz (at) cornell (dot) edu
###
